Inhibition of anti-Fas antibody-induced hepatitis by aminoguanidine in mice

被引:5
|
作者
Okamoto, T
Okabe, S
机构
[1] Nippon Chemiphar Co Ltd, Res Labs, Misato, Saitama 3410005, Japan
[2] Kyoto Pharmaceut Univ, Dept Appl Pharmacol, Kyoto 6078414, Japan
关键词
anti-Fas antibody; aminoguanidine; hepatitis;
D O I
10.1016/S0014-2999(00)00479-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aminoguanidine is an inhibitor of inducible nitric oxide synthase (iNOS) and is of potential clinical usefulness. Treatment of mice with anti-Fas antibodies (150 mu g/kg, i.v.) induced elevation of plasma alanine aminotransferase activity at 4 h and this elevation was inhibited by pretreatment of mice with aminoguanidine (3, 10 and 30 mg/kg, i.p.). The anti-Fas antibody-induced elevation of caspase-3 activity was inhibited by aminoguanidine (30 mg/kg, i.p.), but the addition of aminoguanidine to the cytosol up to 10(-4) M did not inhibit the caspase-3 activity in vitro. Thus, aminoguanidine prevents anti-Fas antibody-induced hepatitis by affecting the apoptotic pathway upstream of caspase-3 activation. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:277 / 280
页数:4
相关论文
共 40 条
  • [21] A short peptide derived from the antisense homology box of Fas ligand induces apoptosis in anti-Fas antibody-insensitive human ovarian cancer cells
    Hayakawa, A
    Kojima, T
    Yokoyama, I
    Suzuki, H
    Tajiri, H
    Nakashima, I
    APOPTOSIS, 2000, 5 (01) : 37 - 41
  • [22] A short peptide derived from the antisense homology box of Fas ligand induces apoptosis in anti-Fas antibody-insensitive human ovarian cancer cells
    A. Hayakawa
    T. Kojima
    I. Yokoyama
    H. Suzuki
    H. Tajiri
    I. Nakashima
    Apoptosis, 2000, 5 : 37 - 41
  • [23] Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
    Tsuda, T
    Ohmori, Y
    Muramatsu, H
    Hosaka, Y
    Takiguchi, K
    Saitoh, F
    Kato, K
    Nakayama, K
    Nakamura, N
    Nagata, S
    Mochizuki, H
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 433 (01) : 37 - 45
  • [24] Video-enhanced microscopic visualization of apoptotic cell death caused by anti-Fas antibody in living human glioma cells.
    Ohta S.
    Yoshida J.
    Yamamoto S.
    Uemura K.
    Wakabayashi T.
    Mizuno M.
    Sakurai T.
    Terakawa S.
    Brain Tumor Pathology, 1998, 15 (1) : 19 - 21
  • [25] Tumor necrosis factor-alpha gene transfer augments anti-fas antibody-mediated apoptosis in human glioma cells
    Mizuno, M
    Yoshida, J
    JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (05): : 543 - 547
  • [26] Inhibition of Fas-mediated fulminant hepatitis in CrmA gene-transfected mice
    Li, XK
    Fujino, M
    Guo, L
    Okuyama, T
    Funeshima, N
    Hashimoto, M
    Okabe, K
    Yaginuma, H
    Mikoshiba, K
    Enosawa, S
    Amemiya, H
    Suzuki, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (01) : 101 - 109
  • [27] Resistance of SKW6 cell to apoptosis induction with anti-Fas antibody upon transduction of a reverse fragment to a cDNA encoding human 6A8 α-mannosidase
    Gengxian Shi
    Yulan Jin
    Zhuangzhi Wang
    Wei Cui
    Yin Liu
    Xun Wang
    Liping Zhu
    Science in China Series C: Life Sciences, 2001, 44 : 365 - 372
  • [28] Resistance of SKW6 cell to apoptosis induction with anti-Fas antibody upon transduction of a reverse fragment to a cDNA encoding human 6A8 α-mannosidase
    Shi, GX
    Jin, YL
    Wang, ZZ
    Cui, W
    Liu, Y
    Wang, X
    Zhu, LP
    SCIENCE IN CHINA SERIES C-LIFE SCIENCES, 2001, 44 (04): : 365 - 372
  • [29] Ticlopidine-induced cholestatic hepatitis with anti-nuclear antibody in serum
    Tsai, MH
    Tsai, SL
    Chen, TC
    Liaw, YF
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2000, 99 (11) : 866 - 869
  • [30] Resistance of SKW6 cell to apoptosis induction with anti-Fas antibody upon transduction of a reverse fragment to a cDNA encoding human 6A8 α-mannosidase
    史耕先
    靳玉兰
    王壮志
    崔巍
    刘音
    王讯
    朱立平
    Science in China(Series C:Life Sciences) , 2001, (04) : 365 - 372